SEARCH:   Advanced

Blood, 1 December 2006, Vol. 108, No. 12, pp. 3898-3905. Prepublished online as a Blood First Edition Paper on August 15, 2006; DOI 10.1182/blood-2006-04-014845. This Article Full Text (PDF) Supplemental Table and Figures All Versions of this Article: blood-2006-04-014845v1 108/12/3898    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Heuser, M. Articles by Ganser, A. Search for Related Content PubMed PubMed Citation Articles by Heuser, M. Articles by Ganser, A. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 4, 2006 Accepted July 18, 2006 High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics Michael Heuser*, Gernot Beutel, Juergen Krauter, Konstanze Dohner, Nils von Neuhoff, Brigitte Schlegelberger, and Arnold Ganser Hannover Medical School, Hannover, Germany University Hospital of Ulm, Ulm, Germany * Corresponding author; email: mheuser{at}bccrc.ca. The translocation t(12;22) involves MN1 and TEL and is rarely found in acute myeloid leukemia (AML). Recently, it has been shown in a mouse model that the fusion protein MN1-TEL can promote growth of primitive hematopoietic progenitor cells (HPC) and, in cooperation with HOXA9, induce AML. We quantified MN1 expression by real-time RT-PCR in 142 adult AML patients with normal cytogenetics treated uniformly in trial AML-SHG 01/99. AML samples were dichotomized at the median MN1 expression. High MN1 expression was significantly correlated with unmutated NPM1 (P<.001), poor response to the first course of induction treatment (P=.02), a higher relapse rate (P=.03), and shorter relapse-free (P=.002) and overall survival (P=.03). In multivariate analysis, MN1 expression was an independent prognostic marker (P=.02) in addition to age and ECOG performance status. Excluding NPM1mutated/FLT3ITDnegative patients, high MN1 expression was associated with shorter relapse-free survival (P=.057). MN1 was highly expressed in some patients with acute lymphoblastic, but not chronic lymphocytic or myeloid leukemia. MN1 was highly expressed in HPC compared to differentiated cells, and was downregulated during in-vitro differentiation of CD34+ cells, suggesting a functional role in HPC. In conclusion, our data suggest MN1 overexpression as a new prognostic marker in AML with normal cytogenetics. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Heuser, L. M. Sly, B. Argiropoulos, F. Kuchenbauer, C. Lai, A. Weng, M. Leung, G. Lin, C. Brookes, S. Fung, et al. Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal Blood, November 5, 2009; 114(19): 3983 - 3993. [Abstract] [Full Text] [PDF] K. H. Metzeler, A. Dufour, T. Benthaus, M. Hummel, M.-C. Sauerland, A. Heinecke, W. E. Berdel, T. Buchner, B. Wormann, U. Mansmann, et al. ERG Expression Is an Independent Prognostic Factor and Allows Refined Risk Stratification in Cytogenetically Normal Acute Myeloid Leukemia: A Comprehensive Analysis of ERG, MN1, and BAALC Transcript Levels Using Oligonucleotide Microarrays J. Clin. Oncol., October 20, 2009; 27(30): 5031 - 5038. [Abstract] [Full Text] [PDF] E. R. Mardis, L. Ding, D. J. Dooling, D. E. Larson, M. D. McLellan, K. Chen, D. C. Koboldt, R. S. Fulton, K. D. Delehaunty, S. D. McGrath, et al. Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome N. Engl. J. Med., September 10, 2009; 361(11): 1058 - 1066. [Abstract] [Full Text] [PDF] M. Heuser, F. Kuchenbauer, B. Argiropoulos, S. Sekulovic, M. Leung, M. Stasiak, A. Ganser, and R. K. Humphries Priming reloaded? Blood, July 23, 2009; 114(4): 925 - 926. [Full Text] [PDF] X. Zhang, D. R. Dowd, M. C. Moore, T. A. Kranenburg, M. A. Meester-Smoor, E. C. Zwarthoff, and P. N. MacDonald Meningioma 1 Is Required for Appropriate Osteoblast Proliferation, Motility, Differentiation, and Function J. Biol. Chem., July 3, 2009; 284(27): 18174 - 18183. [Abstract] [Full Text] [PDF] C. M. Santamaria, M. C. Chillon, R. Garcia-Sanz, C. Perez, M. D. Caballero, F. Ramos, A. G. de Coca, J. M. Alonso, P. Giraldo, T. Bernal, et al. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia Blood, July 2, 2009; 114(1): 148 - 152. [Abstract] [Full Text] [PDF] C. Langer, G. Marcucci, K. B. Holland, M. D. Radmacher, K. Maharry, P. Paschka, S. P. Whitman, K. Mrozek, C. D. Baldus, R. Vij, et al. Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study J. Clin. Oncol., July 1, 2009; 27(19): 3198 - 3204. [Abstract] [Full Text] [PDF] Z. Li, G. Beutel, M. Rhein, J. Meyer, C. Koenecke, T. Neumann, M. Yang, J. Krauter, N. von Neuhoff, M. Heuser, et al. High-affinity neurotrophin receptors and ligands promote leukemogenesis Blood, February 26, 2009; 113(9): 2028 - 2037. [Abstract] [Full Text] [PDF] M. Heuser, D. B. Yap, M. Leung, T. R. de Algara, A. Tafech, S. McKinney, J. Dixon, R. Thresher, B. Colledge, M. Carlton, et al. Loss of Mll5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation Blood, February 12, 2009; 113(7): 1432 - 1443. [Abstract] [Full Text] [PDF] W. Liu, Y. Lan, E. Pauws, M. A. Meester-Smoor, P. Stanier, E. C. Zwarthoff, and R. Jiang The Mn1 transcription factor acts upstream of Tbx22 and preferentially regulates posterior palate growth in mice Development, December 1, 2008; 135(23): 3959 - 3968. [Abstract] [Full Text] [PDF] C. Guy, A. Gilkes, R. Gale, D. C. Linch, R. Hills, and A. K. Burnett The Impact of MN1 Over-Expression on the Outcome of Younger Patients with AML Treated with Intensive Chemotherapy with or without ATRA Therapy Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 2978 - 2978. [Abstract] M. A. Meester-Smoor, M. J.F.W. Janssen, G. C. Grosveld, A. de Klein, W. F.J. van IJcken, H. Douben, and E. C. Zwarthoff MN1 affects expression of genes involved in hematopoiesis and can enhance as well as inhibit RAR/RXR-induced gene expression Carcinogenesis, October 1, 2008; 29(10): 2025 - 2034. [Abstract] [Full Text] [PDF] P. Kumpers, C. Koenecke, H. Hecker, J. Hellpap, R. Horn, W. Verhagen, S. Buchholz, B. Hertenstein, J. Krauter, M. Eder, et al. Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies Blood, September 1, 2008; 112(5): 2139 - 2148. [Abstract] [Full Text] [PDF] C. Langer, M. D. Radmacher, A. S. Ruppert, S. P. Whitman, P. Paschka, K. Mrozek, C. D. Baldus, T. Vukosavljevic, C.-G. Liu, M. E. Ross, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study Blood, June 1, 2008; 111(11): 5371 - 5379. [Abstract] [Full Text] [PDF] B. Lowenberg Diagnosis and Prognosis in Acute Myeloid Leukemia -- The Art of Distinction N. Engl. J. Med., May 1, 2008; 358(18): 1960 - 1962. [Full Text] [PDF] N. Watanabe-Okochi, J. Kitaura, R. Ono, H. Harada, Y. Harada, Y. Komeno, H. Nakajima, T. Nosaka, T. Inaba, and T. Kitamura AML1 mutations induced MDS and MDS/AML in a mouse BMT model Blood, April 15, 2008; 111(8): 4297 - 4308. [Abstract] [Full Text] [PDF] B. Lowenberg Acute Myeloid Leukemia: The Challenge of Capturing Disease Variety Hematology, January 1, 2008; 2008(1): 1 - 11. [Abstract] [Full Text] [PDF] T. Haferlach Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia Hematology, January 1, 2008; 2008(1): 400 - 411. [Abstract] [Full Text] [PDF] M. Heuser, B. Argiropoulos, F. Kuchenbauer, E. Yung, J. Piper, S. Fung, R. F. Schlenk, K. Dohner, T. Hinrichsen, C. Rudolph, et al. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML Blood, September 1, 2007; 110(5): 1639 - 1647. [Abstract] [Full Text] [PDF] J. R. Pollack A Perspective on DNA Microarrays in Pathology Research and Practice Am. J. Pathol., August 1, 2007; 171(2): 375 - 385. [Abstract] [Full Text] [PDF] C. Slape, H. Hartung, Y.-W. Lin, J. Bies, L. Wolff, and P. D. Aplan Retroviral Insertional Mutagenesis Identifies Genes that Collaborate with NUP98-HOXD13 during Leukemic Transformation Cancer Res., June 1, 2007; 67(11): 5148 - 5155. [Abstract] [Full Text] [PDF] K. Mrozek, G. Marcucci, P. Paschka, S. P. Whitman, and C. D. Bloomfield Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood, January 15, 2007; 109(2): 431 - 448. [Abstract] [Full Text] [PDF] H. Dohner Implication of the Molecular Characterization of Acute Myeloid Leukemia Hematology, January 1, 2007; 2007(1): 412 - 419. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020